Clinical Trials Logo

Clinical Trial Summary

Urinary tract stones may form in the kidneys or along the ureteric tracts and when left untreated, may result in complications such as pain, bleeding, infection and obstruction. ESWL (extra-corporeal shock wave lithotripsy) has been shown to be an effective and safe method of treatment for kidney and ureteric stones in-situ. In our centre, ESWL is done on an outpatient basis with oral pain killers in the weeks following treatment. Patients are also instructed to increase their fluid intake during this period to expedite the clearance of stone fragments. There have been studies to show that pain caused by stones is due to smooth muscle spasm along the ureters, possibly mediated by alpha-receptors. Alpha-blockers have been shown to improve the expulsion of stones and also improve pain relief when used alone, or together with ESWL treatment. In our study, we seek to investigate if alpha-blocker therapy (Alfuzosin) increases stone free rates and improves pain control after ESWL for renal and ureteric stones. The potential benefits include a higher rate of stone clearance and better pain control


Clinical Trial Description

Urinary tract stones may form in the kidneys or along the ureteric tracts and when left untreated, may result in complications such as pain, bleeding, infection and obstruction. ESWL (extra-corporeal shock wave lithotripsy) has been shown to be an effective and safe method of treatment for kidney and ureteric stones in-situ. In our centre, ESWL is done on an outpatient basis with oral pain killers in the weeks following treatment. Patients are also instructed to increase their fluid intake during this period to expedite the clearance of stone fragments. Alpha1-adrenergic blockers have been shown to improve stone free rates in renal stones and lower ureteric stones. Tamsulosin has been the agent most commonly investigated. There have been no studies done to study the effectiveness of Alfuzosin in stone treatment. Alfuzosin has been shown to be effective in treating benign prostatic hypertrophy, and has a good safety profile. Deliveliotis et al has shown that alfuzosin improves symptoms and quality of life in patients with double-J stents.

This is a prospective, randomised, double-blind, placebo-controlled study involving patients undergoing ESWL for renal and ureteric stones. Exclusion criteria applies (please see below). The patients will be randomised into 2 groups: study VS control. Randomisation is done by using a computer generated list with block randomisation, assigning consecutive patients to either treatment arms. Our standard treatment is intravenous pethidine 50mg and intravenous maxolon 10mg at the onset of the ESWL session, followed by oral analgesics- NSAIDs with a gastroprotective agent. For this study, we will standardise all to oral naproxen 550mg BD with oral omeprazole 20mg BD. The study group will receive the standard treatment, with oral alfuzosin 10mg ON for 1 month, while the control group will receive a placebo. Patients will be given a diary in which to chart their pain scores, use of analgesics, episodes of pain, passage of stones, side-effects of the medications and complications of treatment. At the end of one month, all patients will be called back for review. Stone free status is ascertained with an X-ray, and the diary will be collected for further analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00388271
Study type Interventional
Source Singapore General Hospital
Contact
Status Withdrawn
Phase Phase 3
Start date October 2006
Completion date December 2007

See also
  Status Clinical Trial Phase
Recruiting NCT04924790 - The Effect of the COVID-19 on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT05574517 - Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter N/A
Recruiting NCT02298465 - ESWL for Distal Ureteric Stone: Supine Versus Prone N/A
Active, not recruiting NCT01973088 - Screening and Identification of Human Urate Transporter hURAT1 MicroRNA N/A
Recruiting NCT01884870 - Silent Ureteral Stone: Impact on Renal Function and Kidney Anatomy N/A
Active, not recruiting NCT00575432 - Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy
Completed NCT05027971 - Flexiva Pulse Registry
Terminated NCT00199524 - Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Phase 4
Recruiting NCT05048706 - SP TLF Versus Ho:YAG Laser N/A
Not yet recruiting NCT04110574 - Computed Tomography Evaluation of Urinary Stones Densities Compared to in Vitro Analysis of Its Chemical Composition
Recruiting NCT02594631 - Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial. Phase 4
Completed NCT00857090 - Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones Phase 1/Phase 2
Completed NCT04112160 - Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal Phase 2
Completed NCT04594161 - Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis N/A
Not yet recruiting NCT04796792 - Ultrasound to Facilitate Stone Passage N/A
Recruiting NCT05270421 - Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi Phase 3
Completed NCT02983409 - Analysis the Relationship Between the Abdomen CT and Outcomes in Acute Urinary Stone Patients N/A
Not yet recruiting NCT00397397 - Comparative Treatment Study in Patients With Lower Ureteral Stones Phase 0
Completed NCT00199459 - Proteomic Study of Urinary Stone Disease N/A